X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
colorectal cancer (6) 6
index medicus (6) 6
aged (5) 5
cancer therapies (5) 5
colorectal neoplasms - drug therapy (5) 5
female (5) 5
humans (5) 5
male (5) 5
metastasis (5) 5
middle aged (5) 5
oncology (5) 5
clinical trials (4) 4
colorectal neoplasms - pathology (4) 4
hematology, oncology and palliative medicine (4) 4
adult (3) 3
bevacizumab (3) 3
cancer patients (3) 3
colorectal neoplasms - mortality (3) 3
disease-free survival (3) 3
fluorouracil (3) 3
medical prognosis (3) 3
medical research (3) 3
patients (3) 3
studies (3) 3
1st-line treatment (2) 2
aged, 80 and over (2) 2
antineoplastic agents - therapeutic use (2) 2
camptothecin - analogs & derivatives (2) 2
cancer (2) 2
care and treatment (2) 2
data collection (2) 2
irinotecan (2) 2
leucovorin (2) 2
medicine, experimental (2) 2
mutation (2) 2
oxaliplatin (2) 2
phenylurea compounds - therapeutic use (2) 2
prognosis (2) 2
proportional hazards models (2) 2
proteins (2) 2
pyridines - therapeutic use (2) 2
research (2) 2
survival (2) 2
tumors (2) 2
1506 (1) 1
abridged index medicus (1) 1
acquired-resistance (1) 1
adenocarcinoma (1) 1
adenocarcinoma - blood (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - secondary (1) 1
adolescent (1) 1
adverse drug reaction reporting systems (1) 1
aflibercept (1) 1
analysis (1) 1
angiogenesis (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antidepressants (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
biomarkers (1) 1
biomarkers, tumor - blood (1) 1
biomarkers, tumor - genetics (1) 1
breast neoplasms - drug therapy (1) 1
breast neoplasms - pathology (1) 1
camptothecin - administration & dosage (1) 1
camptothecin - adverse effects (1) 1
carcinoma (1) 1
carcinomatosis (1) 1
cediranib (1) 1
chemotherapy (1) 1
class i phosphatidylinositol 3-kinases (1) 1
clinical trials as topic (1) 1
clinical trials, phase iii as topic (1) 1
clinical-practice (1) 1
colon (1) 1
colorectal carcinoma (1) 1
colorectal neoplasms - blood (1) 1
colorectal neoplasms - genetics (1) 1
combination chemotherapy (1) 1
complications and side effects (1) 1
concordance (1) 1
data analysis (1) 1
data bases (1) 1
databases (1) 1
deoxyribonucleic acid--dna (1) 1
development and progression (1) 1
disease progression (1) 1
dna (1) 1
dna mutational analysis (1) 1
dna, neoplasm - blood (1) 1
dna, neoplasm - genetics (1) 1
double-blind (1) 1
double-blind method (1) 1
drug resistance (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 937 - 948
Summary Background Tumour mutational status is an important determinant of the response of metastatic colorectal cancer to targeted treatments. However, the... 
Hematology, Oncology and Palliative Medicine | KRAS MUTATIONS | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | RANDOMIZED PHASE-III | INHIBITS GROWTH | ACQUIRED-RESISTANCE | FLUOROURACIL | PLACEBO PLUS | TUMOR-GROWTH | Predictive Value of Tests | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Clinical Trials, Phase III as Topic | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Real-Time Polymerase Chain Reaction | Precision Medicine | Receptor, TIE-1 - blood | Phosphatidylinositol 3-Kinases - blood | Genetic Predisposition to Disease | Adenocarcinoma - blood | ras Proteins - blood | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Phenotype | Class I Phosphatidylinositol 3-Kinases | Biomarkers, Tumor - genetics | ras Proteins - genetics | Patient Selection | DNA, Neoplasm - blood | Female | Adenocarcinoma - genetics | Retrospective Studies | Pyridines - therapeutic use | Colorectal Neoplasms - mortality | Colorectal Neoplasms - blood | Kaplan-Meier Estimate | Proportional Hazards Models | Phenylurea Compounds - therapeutic use | Proto-Oncogene Proteins B-raf - blood | Proto-Oncogene Proteins - genetics | Treatment Outcome | Randomized Controlled Trials as Topic | Biomarkers, Tumor - blood | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Proto-Oncogene Proteins B-raf - genetics | Aged | DNA, Neoplasm - genetics | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins - blood | Adenocarcinoma - mortality | Medical colleges | Medical research | Cancer patients | Prognosis | Liver | DNA | Colorectal cancer | Genetic research | Medicine, Experimental | Metastasis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 12, pp. 1709 - 1719
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 499 - 508
Journal Article
Journal Article
ESMO Open, ISSN 2059-7029, 04/2018, Volume 3, Issue 3, p. e000347
BackgroundIn the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.